Aspira Pathlab & Diagnostics Limited Stock Price Today (NSE: ASPIRA)
Aspira Pathlab & Diagnostics Limited
Fundamental Score
Aspira Pathlab & Diagnostics Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Aspira Pathlab & Diagnostics Limited share price today is ₹55.85, down 5.60% on NSE/BSE as of 30 March 2026. Aspira Pathlab & Diagnostics Limited (ASPIRA) is a Small-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹71.80 (Cr). The 52-week high for ASPIRA share price is ₹81.00 and the 52-week low is ₹50.49. At a P/E ratio of 29.92x, ASPIRA is currently trading below its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 32.96% and a debt-to-equity ratio of 1.12.
Aspira Pathlab & Diagnostics Limited Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Aspira Pathlab & Diagnostics Limited Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Aspira Pathlab & Diagnostics Share Price: A Conservative Value Investor's Perspective
Within the Healthcare Service Provider industry, a critical yet often overlooked aspect is the quality of service and trustworthiness. Patients and referring physicians place immense value on accuracy and reliability, creating a strong preference for established brands. This analysis examines the investment potential of Aspira Pathlab & Diagnostics Limited, focusing on capital preservation, particularly concerning the current Aspira Pathlab & Diagnostics share price of ₹66.87. This is part of an 80-parameter fundamental audit verified by Sweta Mishra.
Aspira Pathlab & Diagnostics Limited exhibits a Price-to-Earnings (PE) ratio of 29.92. While PE ratios offer a snapshot of valuation, they must be viewed in conjunction with other financial health indicators. Comparing Aspira Pathlab & Diagnostics Limited with peers requires careful consideration. For example,
Suraksha Diagnostic Ltd may have a different management approach which could impact investor confidence, even if financial metrics appear comparable on the surface. Assessing management's track record in capital allocation and navigating industry challenges is paramount for a value investor.The company's Return on Capital Employed (ROCE) of 17.04% is a positive sign. ROCE indicates how effectively a company is using its capital to generate profits. A consistently high ROCE, like Aspira's, can suggest the presence of a competitive advantage or "moat," as it reflects the company's ability to generate superior returns compared to its peers. However, it’s critical to determine if this ROCE is sustainable and resistant to competitive pressures within the diagnostic services sector.
While this financial overview provides a preliminary assessment, a complete due diligence process is essential. Factors such as debt levels, cash flow generation, and future growth prospects all play vital roles in determining the long-term investment viability of Aspira Pathlab & Diagnostics Limited. Furthermore, monitoring industry trends and regulatory changes are crucial for maintaining a conservative investment approach.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Aspira Pathlab & Diagnostics Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of ASPIRA across key market metrics for learning purposes.
Positive Indicators
5 factors identified
Strong Return on Equity (32.96%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (17.04%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 29.92 vs Industry: 39.28)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (740.00%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Elevated Debt Levels (D/E: 1.12)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Low Promoter Commitment (18.39%)
Observation: Reduced promoter stake may indicate limited confidence.
Analysis: Low promoter holding may raise questions about management commitment.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Aspira Pathlab & Diagnostics Limited Financial Statements
Comprehensive financial data for Aspira Pathlab & Diagnostics Limited including income statement, balance sheet and cash flow
About ASPIRA (Aspira Pathlab & Diagnostics Limited)
Aspira Pathlab & Diagnostics Limited is a dynamic and comprehensive healthcare service provider dedicated to delivering accurate and timely diagnostic solutions. With a network of ...state-of-the-art facilities, ASPIRA offers a broad spectrum of diagnostic services, encompassing both routine and specialized testing. From advanced molecular diagnostics to conventional pathology, the company empowers clinicians with critical insights for informed decision-making and improved patient outcomes. Committed to quality and innovation, ASPIRA embraces cutting-edge technologies and rigorous quality control measures to ensure the highest standards of accuracy and reliability across all its diagnostic services. The company's relentless focus on excellence has established it as a trusted partner for healthcare professionals and patients alike. At the heart of ASPIRA's diagnostic capabilities lies an extensive portfolio of services designed to cater to diverse clinical needs. ASPIRA provides a wide range of specialized testing services, encompassing areas such as molecular diagnostics, cytogenetics, and advanced imaging. These sophisticated diagnostic tools allow for the detection of subtle disease markers, personalized treatment strategies, and enhanced patient management. Beyond specialized testing, ASPIRA offers a comprehensive suite of routine diagnostics, including clinical chemistry, hematology, and microbiology. This comprehensive approach enables the company to serve as a one-stop solution for a wide array of diagnostic requirements, simplifying the process for healthcare providers and ensuring timely access to essential diagnostic information. Driven by a commitment to accessibility and patient-centric care, ASPIRA strives to expand its reach and make quality diagnostics available to a wider population. The company strategically positions its diagnostic centers to ensure convenient access for patients in both urban and rural areas. Furthermore, ASPIRA leverages digital technologies to streamline the diagnostic process, offering online appointment booking, secure access to test results, and teleconsultation services. By embracing technology and innovation, ASPIRA aims to empower patients with greater control over their healthcare journey, facilitating informed decision-making and promoting proactive health management. ASPIRA Pathlab & Diagnostics Limited is steadfast in its mission to be a leading force in transforming healthcare through accurate diagnostics and patient-focused solutions.
Company Details
Key Leadership
Latest News
ASPIRA Share Price: Frequently Asked Questions
What is the current share price of Aspira Pathlab & Diagnostics Limited (ASPIRA)?
As of 30 Mar 2026, 12:07 pm IST, Aspira Pathlab & Diagnostics Limited share price is ₹55.85. The ASPIRA stock has a market capitalisation of ₹71.80 (Cr) on NSE/BSE.
Is ASPIRA share price Overvalued or Undervalued?
ASPIRA share price is currently trading at a P/E ratio of 29.92x, compared to the industry average of 39.28x. Based on this relative valuation, the Aspira Pathlab & Diagnostics Limited stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of ASPIRA share price?
The 52-week high of ASPIRA share price is ₹81.00 and the 52-week low is ₹50.49. These values are updated daily from NSE/BSE price data.
What factors affect the Aspira Pathlab & Diagnostics Limited share price?
Key factors influencing ASPIRA share price include quarterly earnings growth (Sales Growth: 13.15%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Aspira Pathlab & Diagnostics Limited a good stock for long-term investment?
Aspira Pathlab & Diagnostics Limited shows a 5-year Profit Growth of N/A% and an ROE of 32.96%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 1.12 before investing in ASPIRA shares.
How does Aspira Pathlab & Diagnostics Limited compare with its industry peers?
Aspira Pathlab & Diagnostics Limited competes with major peers in the Healthcare Service Provider. Investors should compare ASPIRA share price P/E of 29.92x and ROE of 32.96% against the industry averages to determine competitive standing.
What is the P/E ratio of ASPIRA and what does it mean?
ASPIRA share price has a P/E ratio of 29.92x compared to the industry average of 39.28x. Investors pay ₹30 for every ₹1 of annual earnings.
How is ASPIRA performing according to Bull Run's analysis?
ASPIRA has a Bull Run fundamental score of 24.7/100, indicating concerns requiring careful analysis. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does ASPIRA belong to?
ASPIRA operates in the Healthcare Service Provider industry. This classification helps understand the competitive landscape and sector-specific trends affecting Aspira Pathlab & Diagnostics Limited share price.
What is Return on Equity (ROE) and why is it important for ASPIRA?
ASPIRA has an ROE of 32.96%, which indicates excellent management efficiency. ROE measures how efficiently Aspira Pathlab & Diagnostics Limited generates profits from shareholders capital.
How is ASPIRA debt-to-equity ratio and what does it indicate?
ASPIRA has a debt-to-equity ratio of 1.12, which indicates high leverage that increases financial risk.
What is ASPIRA dividend yield and is it a good dividend stock?
ASPIRA offers a dividend yield of 0.00%, meaning you receive ₹0.00 annual dividend for every ₹100 invested in Aspira Pathlab & Diagnostics Limited shares.
How has ASPIRA share price grown over the past 5 years?
ASPIRA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in ASPIRA and why does it matter?
Promoters hold 18.39% of ASPIRA shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Aspira Pathlab & Diagnostics Limited.
What is ASPIRA market capitalisation category?
ASPIRA has a market capitalisation of ₹72 crores, placing it in the Small-cap category.
How volatile is ASPIRA stock?
ASPIRA has a beta of N/A. A beta > 1 suggests the Aspira Pathlab & Diagnostics Limited stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is ASPIRA operating profit margin trend?
ASPIRA has a 5-year average Operating Profit Margin (OPM) of N/A%, indicating the company's operational efficiency.
How is ASPIRA quarterly performance?
Recent quarterly performance shows Aspira Pathlab & Diagnostics Limited YoY Sales Growth of 13.15% and YoY Profit Growth of 740.00%.
What is the institutional holding pattern in ASPIRA?
ASPIRA has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Aspira Pathlab & Diagnostics Limited stock.